ClC-5 chloride channel and kidney stones : what is the link? by Silva, Ian Victor et al.
315
Braz J Med Biol Res 34(3) 2001
ClC-5 and nephrolithiasisBrazilian Journal of Medical and Biological Research (2001) 34: 315-323
ISSN 0100-879X
ClC-5 chloride channel and kidney
stones: what is the link?
Laboratório de Fisiologia Renal, Instituto de Biofísica Carlos Chagas Filho,
Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil
I.V. Silva,
M.M. Morales
and A.G. Lopes
Abstract
Nephrolithiasis is one of the most common diseases in the Western
world. The disease manifests itself with intensive pain, sporadic
infections, and, sometimes, renal failure. The symptoms are due to the
appearance of urinary stones (calculi) which are formed mainly by
calcium salts. These calcium salts precipitate in the renal papillae and/
or within the collecting ducts. Inherited forms of nephrolithiasis
related to chromosome X (X-linked hypercalciuric nephrolithiasis or
XLN) have been recently described. Hypercalciuria, nephrocalcino-
sis, and male predominance are the major characteristics of these
diseases. The gene responsible for the XLN forms of kidney stones
was cloned and characterized as a chloride channel called ClC-5. The
ClC-5 chloride channel belongs to a superfamily of voltage-gated
chloride channels, whose physiological roles are not completely un-
derstood. The objective of the present review is to identify recent
advances in the molecular pathology of nephrolithiasis, with emphasis
on XLN. We also try to establish a link between a chloride channel like
ClC-5, hypercalciuria, failure in urine acidification and protein en-
docytosis, which could explain the symptoms exhibited by XLN
patients.
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Is nephrolithiasis a matter of
imbalances in mineral metabolism?
Nephrolithiasis (or kidney stones) is one
of the most common diseases in countries
like the USA, United Kingdom, Japan, and
Brazil (1-4). Most of the patients present
recurrent kidney stones and metabolic disor-
ders (5-7). Male patients predominate, but
about 30% of patients are female (1-3).
Most calculi found in patients with kid-
ney stones are formed by calcium salts, mainly
calcium phosphate and calcium oxalate (8-
10). Calculi formed by cystine (a dimer of
cysteine), urate, and struvite (Mg(NH4)PO4)
are found less frequently (1). The fact that
calculi are mainly formed by calcium salts
has led many investigators to speculate about
a possible problem in calcium homeostasis
(1). Although several investigators have ex-
plored this hypothesis, there are no conclu-
sive data about this mechanism of stone for-
mation.
Important advances have been recently
made with the identification of inherited
forms of nephrolithiasis. Several genes have
been identified by genetic mapping of fami-
lies with a history of kidney stones. Among
these genes are the cystine transporter, which
is defective in autosomal recessive cysti-
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nuria (11), the calcium sensing receptor (12),
and the voltage-gated chloride channel ClC-
5 (for a review, see Ref. 13), on which we
focus this review.
Data involving ClC-5 in the pathogenesis
of nephrolithiasis have been recently re-
viewed by Scheinman (14). In the present
review we point out the postulated roles that
ClC-5 could have in the pathogenesis of
nephrolithiasis. Also, we try to establish a
link between this chloride channel and stone
formation.
The ClC-5 chloride channel and
X-linked recessive nephrolithiasis:
are they just variants or different
diseases?
Dents disease was first reported by Dent
and Friedman in 1964 (15). At that time, they
identified this disease as a form of Fanconis
syndrome due to impairment of renal acidifi-
cation similar to that observed in such pa-
tients (15). Besides the renal acidification
impairment, Dents disease patients also ex-
hibited rickets, hypercalciuria, nephrocalci-
nosis, low molecular weight (LMW) pro-
teinuria, and nephrolithiasis (14-17). Pro-
gressive renal failure may occur in the late
stages of Dents disease (14,16,17).
Several reports have identified other syn-
dromes with phenotypes similar to that of
Dents disease. These diseases have been
called X-linked recessive nephrolithiasis in
the USA, X-linked recessive hypophospha-
temic rickets in Italy, and LMW proteinuria
with hypercalciuria and nephrocalcinosis in
Japan (14). Although these syndromes have
hypercalciuria, LMW proteinuria, and neph-
rocalcinosis in common, rickets and renal
failure are not always present in all of them
(16). Table 1 summarizes the common symp-
toms and their occurrence among the vari-
ants. Also, Table 1 shows mutations in the
ClC-5 characterizing idiopathic nephrolithi-
asis in the USA and the characteristics of
nephrolithiasis in Brazil.
Pedigree analysis of families with Dents
disease revealed that this syndrome may be
linked to the X chromosome. After 30 years,
Thakker and colleagues (18-21) finally iden-
tified the locus responsible for the gene de-
fect in the 11.22 region of the X chromo-
some. Further isolation of the gene encoded
by this region showed that its product was a
chloride channel, called ClC-5 (19).
The ClC-5 chloride channel belongs to a
family of voltage-gated chloride channels
and its predicted structure is shown in Figure
1. This growing family already has 9 cloned
members (22,23). At least two other mem-
bers of this family, ClC-1 and ClC-KB, are
involved in diseases.
ClC-1 is defective in Thomsens myoto-
nia. There is evidence that the wild-type
ClC-1 channel maintains the membrane po-
tential in muscle cells after excitation (19,21).
Thus, loss of function of ClC-1 leads to
permanent muscle excitation and excessive
contractile activity. A kidney-specific chlo-
ride channel, ClC-KB, was shown to be mu-
Table 1 - A summary of the main symptoms caused by the variants of X-linked
hypercalciuric nephrolithiasis (XLN) and the symptoms detected in a study of idiopathic
nephrolithiasis patients in the USA and Brazil (Refs. 5,60).
Male predominance, hypercalciuria, and low molecular weight (LMW) proteinuria are
present in all XLN patients. However, rickets, calcium stones, and renal failure vary
among syndromes. Several mutations in ClCN5 are found in these syndromes. Never-
theless, mutation in ClC-5 was detected in just one person among 32 patients with
idiopathic hypercalciuric nephrolithiasis. No study addressing ClCN5 mutations or a
characterization of a syndrome closely related to Dent’s disease is available for the
Brazilian patients. ND, Not determined. (Modified from Ref. 17, with permission).
*Found in just one patient (Ref. 60).
X-Linked recessive XLN Dent’s X-Linked LMW proteinuria/ Idiopathic
syndrome disease recessive nephrocalcinosis nephrolithiasis
rickets
Source of reports USA, UK Italy, Japan USA Brazil
Canada France
LMW proteinuria + + + + - ND
Hypercalciuria + + + + + +
Nephrocalcinosis + + + - + +
Calcium stones - + + - + +
Renal failure - + + + - ND
Male predominance + + + - + -
Rickets - + + + - -
ClCN5 mutations + + + + +* ?
317
Braz J Med Biol Res 34(3) 2001
ClC-5 and nephrolithiasis
tated in Bartters syndrome which is charac-
terized by electrolyte loss (24). The localiza-
tion of ClC-KB in the basolateral membrane
of the thin ascending limb of Henles loop as
well as its regulation by dehydration suggest
a role in the mechanism of urinary concen-
tration (25).
Lloyd and coworkers (26) showed that
the mutant ClC-5 found in patients with
Dents disease has lower conductance than
the wild-type chloride channel. They also
characterized several mutations of the ClC-5
gene in patients with X-linked recessive neph-
rolithiasis, X-linked hypophosphatemic rick-
ets, and LMW proteinuria with hypercalci-
uria and nephrocalcinosis, showing that these
diseases are just variations of a single pa-
thology (26,27). All mutants exhibited loss
of function when compared to wild-type
ClC-5, suggesting that ClC-5 is needed for
normal renal function. These syndromes were
then grouped under the same name of X-
linked hypercalciuric nephrolithiasis (XLN)
by Scheinman (14).
The information that the ClC-5 channel
could be the molecular entity responsible for
stone formation led several researchers to
investigate the molecular basis of the dis-
ease. Although mutations were found within
the ClC-5 gene, no apparent relation be-
tween stone formation and a chloride chan-
nel was detected. The literature on ClC-5
and XLN will be discussed in the next sec-
tions.
ClC-5 chloride channel and protein
endocytosis
The majority of patients with XLN also
have LMW proteinuria (14,26-28). It is well
known that LMW proteins are reabsorbed in
the S2 and S3 segments of the proximal tu-
bules, where several proteins filtered by the
glomerulus are endocytosed and degraded
within the lysosomes, providing the uptake
of the amino acids (29).
ClC-5 is found in the S2 and S3 segments
of proximal tubules, mainly in immediately
early endosomes (30-35). Also, Devuyst et
al. (35) demonstrated that proximal tubule
cells transfected with ClC-5 are able to
endocytose albumin and that the channel
colocalizes with the albumin present in the
endosomes. These data suggest a possible
role of ClC-5 in non-receptor-mediated en-
docytosis, explaining the LMW proteinuria
found in such patients.
Some hypotheses about the role of ClC-5
in the endosomes have been raised. Within
the lysosomes several proteases work in an
L200R S244L
S520P
Extracellular
Intracellular
W279X
G506E
R648X
R704X
HOOC-
NH2
Figure 1 - Predicted two-dimen-
sional structure of the ClC-5
chloride channel. Deduction of
amino acids from ClC-5 cDNA
predicts 13 transmembrane do-
mains. Although there is a po-
tential site for cAMP-dependent
protein kinase, analogs of cAMP
do not change the current of the
ClC-5 channel (Refs. 40,41).
Some common mutations in
XLN patients are represented by
black circles and the mutated
amino acids are indicated (ob-
tained from Ref. 26).
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acidic environment provided by the vacuolar
H+-ATPase (31-33). The transport of a posi-
tively charged ion such as H+ should be
followed by an anion, such as Cl-, to main-
tain electroneutrality within the organelle.
As long as it is present in the endosomes,
ClC-5 may allow the transport of chloride
through the endosomal membrane (31,32,34,
35). Therefore, loss of ClC-5 function may
lead to impairment of H+-ATPase activity
which would decrease the pH inside the
endosome. Moreover, the failure in organelle
acidification may lead to a decrease in pro-
tein endocytosis, and therefore, to the LMW
proteins excreted in urine by XLN patients.
ClC-5 is found in endosomes but not in
lysosomes (31-33). Acidic secretion also
occurs in lysosomes and therefore they should
also have a system for Cl- transport. Hence,
chloride channels other than ClC-5 may be
present in lysosomes (34,35). Thus, it is
reasonable to assume that ClC-5 contributes
to Cl- transport in the late endosome, but it is
not clear how the channel works when the
endosome becomes a lysosome.
Deficiency in endocytosis is supposed to
be lethal due to its role in cellular nutrition.
In rats, ClC-5 is expressed in other tissues
besides the kidney, such as brain, lungs,
liver, endothelial cells, and colon (31-33,36).
In addition, the human ClC-5 channel is also
expressed in endothelial cells, suggesting
that the distribution of ClC-5 may not be
restricted to the kidney (37). It is well known
that protein endocytosis takes place in liver,
endothelial cells, and colon. However, in
XLN patients no disorders in endocytosis
are observed in any other organs in addition
to the kidney. Moreover, neither symptoms
due to chloride channel defects nor dysfunc-
tion in endocytosis were detected in the en-
dothelium. Thus, it is not understood how
this important function could be impaired
only in the kidney.
Several investigators have postulated that
in the renal tubule the calculi are cleared by
endocytosis (8,9,38,39). This mechanism
would lead to fewer stones, lesser calculus
formation, and thus, amelioration of the
symptoms. Thus, besides having a role in
protein endocytosis, the ClC-5 channel may
also be responsible for the clearance of the
calculi formed within the kidney tubules
since both protein and calculi are endocytosed
by similar mechanisms (29,38,39). Taken
together, the data addressing the role of
ClC-5 in protein endocytosis indicate that
ClC-5 may also be important for calculus
clearance. However, further studies are nec-
essary to clarify its role in calculus endocy-
tosis.
ClC-5 chloride channel and urine
acidification
Alkaline urine is a common sign found in
Fanconis syndrome patients (15). Although
Dents disease is currently characterized as
an independent pathology, a urine acidifica-
tion disorder was also found in some pa-
tients (13-17). It is well known that alkaline
urine enhances the precipitation of calcium
salts resulting in kidney stones (1,8,9). How-
ever, urine alkalization is not as widespread
as hypercalciuria and LMW proteinuria in
XLN patients (14-17).
Since the first report of ClC-5 mRNA
localization several speculations have been
made about its role in urinary acidification
(32,40-43). ClC-5 mRNA and protein are
expressed in the intercalated cells of collect-
ing ducts (32,33,38,44). These cells are re-
sponsible for proton (H+) secretion and, there-
fore, urine acidification. Working independ-
ently, Gunther et al. (33) and Sakamoto and
coworkers (44) showed that the ClC-5 pro-
tein colocalizes with H+-ATPase on the
plasma membranes of type A intercalated
cells from collecting ducts.
It is reasonable to assume that there should
be Cl- conductance to maintain electroneu-
trality of H+ secretion as well as within the
endosome. To propose that Cl- secretion
may occur through the ClC-5 channel it is
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necessary to show that ClC-5 is also ex-
pressed on the luminal plasma membrane, as
demonstrated by Gunther and coworkers (33).
In agreement with Gunther and coworkers,
Friedrich et al. (45) have shown that ClC-5 is
indeed expressed as plasma membrane con-
ductance in Xenopus oocytes. In addition,
Mo et al. (46) demonstrated that ClC-5 is
inhibited by a decrease in extracellular pH.
Therefore, the ClC-5 channel is sensitive to
mild changes in pH, with down-regulation of
the channel when the pH decreases. This
seems to be an excellent regulatory mechan-
ism in both the intra-endosomal space and
the tubular lumen. However, some contra-
dictory data have ruled out this hypothesis.
First of all, Luyckx et al. (34) did not
show the expression of ClC-5 in intercalated
cells. They showed that this channel is mainly
present in subcellular compartments but not
on the plasma membrane. Also, animals with
lower expression of ClC-5 do not have any
problem in urine acidification when com-
pared with normal littermates (47). In fact,
despite the pattern of expression and its regu-
lation by pH, there are no other data consis-
tently relating ClC-5 dysfunction to urine
alkalization. Once again, further experiments
are necessary to confirm the role of ClC-5 in
urine acidification.
The role of ClC-5 in mineral
metabolism
Hypercalcuria is another major symptom
of XLN (14-17). The hypothesis that higher
levels of urinary calcium lead to precipita-
tion of calcium salts and then to stone forma-
tion is well accepted today (1,2,8,9). Al-
though ClC-5 seems to be expressed mainly
in the human kidney (the major site of the
disease), it is also expressed in rat colon,
brain, and lungs (33,34,36-38,48,49) and in
Xenopus oocytes (50).
The distribution of ClC-5 mRNA along
the rat nephron reveals that this chloride
channel is more abundant in the S3 segments
of proximal tubules, in the cortical and med-
ullary thick ascending limb of Henles loop,
and in cortical collecting ducts (CCD) (33,34,
36,37). An independent group using in situ
hybridization further confirmed the expres-
sion of the ClC-5 channel on these segments
(32). The localization of ClC-5 matches the
major sites of calcium reabsorption in the
kidney (51). Thus, localization of ClC-5 in
the nephron segments responsible for cal-
cium reabsorption and for the hypercalciuric
phenotype exhibited by XLN patients sug-
gested a role of ClC-5 in calcium transport.
Therefore, a failure in ClC-5 function would
lead to hypercalciuria. However, the rela-
tionship between ClC-5 and calcium me-
tabolism has only recently been investi-
gated.
Silva et al. (52) have shown that para-
thormone (PTH) regulates ClC-5 expression
in vivo in an animal model of disturbed
calcium homeostasis. The authors showed
that vitamin D-deficient and thyroparathy-
roidectomized animals have a lower (about
50%) expression of ClC-5 mRNA in the
kidney cortex. The expression of ClC-5 re-
turned to normal values when the animals
were treated with PTH. These data are repro-
ducible when the ClC-5 protein is analyzed
by Western blots. It is well known that PTH
enhances calcium reabsorption by the kid-
ney and that the major site of this action is
the kidney cortex (51). Animals with low or
almost no expression of ClC-5 have high
urinary calcium excretion (52). These data
suggest that ClC-5 is necessary for calcium
reabsorption in the kidney.
Although it may be not clear how a chlo-
ride channel could enhance calcium reab-
sorption, Gesek and Friedman (49) showed a
functional chloride channel in cultured CCD
cells which reabsorb calcium under PTH
and calcitonin stimulation. PTH, the major
hormone increasing calcium reabsorption in
the kidney, activates this chloride channel in
CCD cells (49). The mechanism of activa-
tion of this chloride channel would require
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gene expression. Taken together, these data
suggest that ClC-5 could be the chloride
channel involved in this mechanism since
PTH also enhances its expression in vivo.
However, other chloride channels with simi-
lar properties, such as the closely related
ClC-3, are also expressed in CCD cells
(32,53). Therefore, it still is necessary to
determine the molecular identity of the chan-
nel reported by Gesek and Friedman (49).
ClC-5 protein was detected in the plasma
membrane as well as in immediately early
endosomes of the S3 segments and on the
apical membrane of the CCD cells of rat
kidney (33,44). It is well known that these
segments participate in the transcellular
mechanisms of calcium reabsorption (51).
As mentioned above, the loss of ClC-5’s
function leads to hypercalciuria, a widespread
symptom in XLN (14-17). Although failure
of calcium reabsorption is a good hypothesis
to explain the hypersaturation of urine (and
then calculus formation) some clinical find-
ing do not agree with the animal model
proposed by Silva and coworkers (52).
Patients with XLN show elevated serum
vitamin D (1a,25(OH)2 vitamin D3 or calci-
triol) and normal plasma PTH levels, a fact
that is not expected for patients with exces-
sive calcium excretion. These clinical obser-
vations lead to a speculation that hypercalci-
uria could be a secondary mechanism due to
excessive intestinal reabsorption enhanced
by calcitriol (54,55). This hypothesis was
explored by Luyckx and coworkers (47) who
produced an animal (mouse) model with
lower expression of the ClC-5 channel. On a
calcium-restricted diet these mice have a
lower urinary calcium/creatinine ratio. The
authors suggest that enhanced calcium reab-
sorption in the intestine (but not the decrease
in calcium reabsorption in the kidney) leads
to an increase in calcium filtered by the
kidney glomeruli and then hypercalciuria.
In agreement with this hypothesis is the
fact that ClC-5 is expressed in the intestine,
mainly in rat colon and a human colon-
derived cell line HT-29 (37,48,52). It may be
possible that ClC-5 acts on intestinal cal-
cium absorption as well as on kidney cal-
cium reabsorption. However, an enhance-
ment in the intestinal absorption of calcium
would be followed by an increase in serum
calcium compared to control mice. Never-
theless, this enhancement in serum calcium
does not take place in mice or in XLN pa-
tients. Also, an excess of calcium is excreted
in feces by Dents disease patients (14-
17,52,54). Although the intestinal compo-
nent relating ClC-5 dysfunction to kidney
stones may be an important factor for the
pathogenesis of nephrolithiasis, further stud-
ies are necessary to test this hypothesis.
Future perspectives and concluding
remarks
Up to now, approximately 40 papers have
been published about the ClC-5 chloride
channel. Many of them have explored and
characterized the mutations responsible for
the several variants of XLN (20,21,26,28,30,
56-59). Very few papers have focused on the
physiological role and regulation of this chan-
nel (35,47,49). On the other hand, the struc-
ture and function of ClC-5 have not been
studied as extensively as for the other mem-
bers of the ClC family (22,23).
We are aware that many experiments
should be done to address all the questions
raised since the cloning of ClC-5 by Thakker
and coworkers (18,19). The possible roles
attributed to ClC-5 need further investiga-
tion and represent a growing area of re-
search. Important questions need to be an-
swered: 1) Why does XLN, being an X-
linked recessive disease, show symptoms in
female carriers? 2) Why do different mu-
tants exhibit different phenotypes? 3) Does
hypercalciuria lead to body calcium and bone
mass loss, and thus to a rickety phenotype in
children?
Knockout mice could be a good model
for answering the first question. Except for
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the mice with lower ClC-5 expression ob-
tained by Luyckx and coworkers (47), no
other animal model has been developed.
However, it would not be a surprise if ClC-5
knockout mice did not present any of the
symptoms of the human disease. Moreover,
the ClC-5 chromosomal localization is still
unknown. As long as mice are not syngeneic
to humans, it is possible that the murine ClC-
5s locus is not located on chromosome X.
This would impair a genetic analysis of car-
rier females and their offspring. This pedi-
gree analysis is essential to investigate the
inheritance of genetic diseases and it has
been done for XLN as well (24). But if
mouse ClC-5 is located on chromosome X it
would be a good model for the pattern of
inheritance and the variations of symptoms.
Different members of the ClC chloride
channel family have been intensively stud-
ied in terms of structure and function (22,23).
Although ClC-5 may have a structure and
function pattern similar to that of other mem-
bers of the family, such studies have not
been done on ClC-5. Similar studies are
necessary because they could help clarify
why different mutations of ClCN5 may re-
sult in such different phenotypes (20,21,26,
28,30,56-60).
Rickets are not so common as hypercal-
ciuria and nephrolithiasis. However, the rick-
ety phenotype is common in Europe (20,21,
26,27,30,57-59). Recent data suggest a role
of ClC-5 in calcium metabolism (47,52). If
ClC-5 is actually involved in calcium me-
tabolism it could be expected to be expressed
in bone, the major site of calcium storage. So
far its expression has not been analyzed in
bone or in bone cells. As we mentioned
above, ClC-5 has a different pattern of ex-
pression varying from a widespread channel
expressed in Xenopus (51) to an almost tis-
sue-specific channel in humans (19,48,50).
It is possible that ClC-5 may also have a role
in human bone metabolism if it is expressed
in bone. This could represent more evidence
of the growing dysfunction observed in some
XLN patients. However, if ClC-5 has a role
in bone metabolism a growth deficiency
would be expected in mice with lower ex-
pression of ClC-5, but this is not the case
(47). Thus, once again, a fully characterized
animal model would be very important for
the study of XLN phenotypes, or might per-
haps raise more questions about the role of
this chloride channel in this complex dis-
ease.
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